Ardelyx, Inc. (ARDX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
ARDX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ARDX Revenue Analysis (2014–2025)
As of March 2, 2026, Ardelyx, Inc. (ARDX) generated trailing twelve-month (TTM) revenue of $398.2 million, reflecting strong growth of +12.3% year-over-year. The most recent quarter (Q3 2025) recorded $110.3 million in revenue, up 13.0% sequentially.
Looking at the longer-term picture, ARDX's 5-year compound annual growth rate (CAGR) stands at +121.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $407.3 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ARDX's business is primarily driven by Product (57%), Product, IBSRELA (42%), and License (1%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY), ARDX has underperformed the peer group in terms of revenue growth. Compare ARDX vs UTHR →
Peer Comparison
Compare ARDX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARDXCurrent | $398M | +12.3% | +121.9% | -10.1% | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $407.3M | +22.1% | $367.8M | 90.3% | $-40,977,000 | -10.1% |
| 2024 | $333.6M | +168.1% | $283.1M | 84.8% | $-27,950,000 | -8.4% |
| 2023 | $124.5M | +138.6% | $106.7M | 85.7% | $-63,276,000 | -50.8% |
| 2022 | $52.2M | +416.6% | $48.0M | 92.1% | $-63,759,000 | -122.2% |
| 2021 | $10.1M | +33.4% | $9.1M | 90.1% | $-154,346,000 | -1528.6% |
| 2020 | $7.6M | +43.4% | $7.4M | 98.1% | $-90,780,000 | -1199.0% |
| 2019 | $5.3M | +102.6% | $4.7M | 88.6% | $-91,263,000 | -1728.1% |
| 2018 | $2.6M | -93.8% | $2.1M | 82.1% | $-90,947,000 | -3488.6% |
| 2017 | $42.0M | +74.8% | $33.6M | 80.0% | $-65,115,000 | -155.0% |
| 2016 | $24.0M | +0.0% | $22.7M | 94.6% | $-112,895,000 | -469.9% |
See ARDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARDX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARDX vs AGIO
See how ARDX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARDX's revenue growth accelerating or slowing?
ARDX maintains +12.3% revenue growth, in line with its 5-year CAGR of +121.9%. TTM revenue stands at $398M. Growth rate remains consistent with historical average.
What is ARDX's long-term revenue growth rate?
Ardelyx, Inc.'s 5-year revenue CAGR of +121.9% reflects the sustained expansion pattern. Current YoY growth of +12.3% is near this long-term average.
How is ARDX's revenue distributed by segment?
ARDX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.